Febrile neutropenia: Difference between revisions

From IDWiki
(Imported from text file)
Β 
Β 
(8 intermediate revisions by the same user not shown)
Line 1: Line 1:
= Febrile neutropenia / neutropenic fever =

== Definition ==
== Definition ==


Line 8: Line 6:
** Profound neutropenia: ANC < 0.1Γ—10^9^/L
** Profound neutropenia: ANC < 0.1Γ—10^9^/L


== Presentation ==
== Clinical Manifestations ==


* Fever
* Fever
Line 42: Line 40:
== Management ==
== Management ==


* In general, broad-spectrum antimicrobials until fever resolved x48h AND neutrophils > 0.5 AND minimum course of 5-7 days, then consider stepping down to treat underlying infection only
* In general, broad-spectrum antimicrobials until '''fever resolved x48h AND neutrophils > 0.5 AND minimum course of 5-7 days''', then consider stepping down to treat underlying infection only
* Empiric antibiotic choice depends on site but should include Pseudomonal coverage
* Empiric antibiotic choice depends on site but should include pseudomonal coverage
** [[Piptazo]] 4.5g q8h, [[Ceftazidime]] 2g q8h, [[Ciprofloxacin]] 400 q12h and [[gentamicin]] 5-7mg/kg q24h, [[Meropenem]] 1g q8h
** Piptazo 4.5g q8h
** Ceftazidime 2g q8h
** Ciprofloxacin 400 q12h and gentamicin 5-7mg/kg q24h
** Meropenem 1g q8h
* Consider adding other agents empirically if concern for:
* Consider adding other agents empirically if concern for:
** MRSA or SSTI or severe mucositis or septic shock: vancomycin 15mg/kg q12h, reassessed at 48h
** [[MRSA]] or SSTI or severe [[mucositis]] or septic shock: vancomycin 15mg/kg q12h, reassessed at 48h
** Typhlitis: ensure adequate anaerobic coverage, may need to add metronidazole 500mg q12h
** [[Typhlitis]]: ensure adequate anaerobic coverage, may need to add metronidazole 500mg q12h
** VRE: linezolid or daptomycin
** [[VRE]]: linezolid or daptomycin
** ESBL: carbapenem
** [[ESBL]]: carbapenem
** KPC: polymixin-colistin or tigecycline
** [[KPC]]: polymixin-colistin or tigecycline
* If still febrile and neutropenic for 4 to 7 days despite antibiotics, add antifungal (especially if not on prophylaxis)
* If still febrile and neutropenic for 4 to 7 days despite antibiotics, add antifungal (especially if not on prophylaxis)
** Caspofungin 70mg then 50mg daily
** [[Caspofungin]] 70mg then 50mg daily
** Liposomal amphotericin B 3mg/kg daily
** Liposomal [[amphotericin]] B 3mg/kg daily
** Anidulafungin if renal or hepatic dysfunction
** [[Anidulafungin]] if renal or hepatic dysfunction
* In high-risk patients, can consider adding GCSF (Neupogen/Filgrastim)
* In high-risk patients, can consider adding GCSF (Neupogen/Filgrastim)
* In some low-risk patients, can step down to amox/clav AND cipro 750
* In some low-risk patients, can step down to [[amoxicillin-clavulanic acid]] AND [[ciprofloxacin]] 750
** Expected duration of severe neutropenia ≀7 days, AND
** Expected duration of severe neutropenia ≀7 days, AND
** No comorbidities or significant hepatic or renal dysfunction
** No comorbidities or significant hepatic or renal dysfunction
Line 67: Line 62:
== Resources ==
== Resources ==


* [http://www.qxmd.com/calculate-online/hematology/febrile-neutropenia-mascc MASCC risk calculator]
* [https://www.mdcalc.com/mascc-risk-index-febrile-neutropenia MASCC risk calculator]


== Further Reading ==
== Further Reading ==


* [https://doi.org/10.1093/cid/cir073 IDSA 2011]
* [https://doi.org/10.1093/cid/cir073 IDSA 2011]

[[Category:Fever syndromes]]
[[Category:Immunocompromised hosts]]

Latest revision as of 18:56, 6 April 2022

Definition

  • Fever: temperature β‰₯38.3Β°C once, or β‰₯38ΒΊC sustained for at least one hour
  • Neutropenia: absolute neutrophil count (ANC) < 1Γ—10^9^/L
    • Severe neutropenia: ANC < 0.5Γ—10^9^/L, or expected to decrease below 0.5Γ—10^9^/L within the next 48 hours
    • Profound neutropenia: ANC < 0.1Γ—10^9^/L

Clinical Manifestations

  • Fever
  • Signs/symptoms of any infection:
    • Oropharynx
    • Chest
    • Skin
    • Anus

Different Diagnosis

  • No focus is identified and no cultures isolated in about half of cases
    • When a focus is identified: respiratory > bloodstream > urinary > SSTI/GI/other
  • Cultures
    • Gram-negative: E. coli > Pseudomonas > Klebsiella > others
    • Gram-positive: Coag-neg Staph > Staph aureus > Enterococcus > other
    • Fungi: Candida (bloodstream), Aspergillus (heme malignancies)

Epidemiology

  • 80% of patients receiving chemotherapy have at least one episode of febrile neutropenia
  • Genetic predisposition like mannose-binding lectin deficiency doubles the duration of fever

Investigations

  • Blood cultures from all lines, including central lines, repeated at least every 72h if it continues
  • Urinalysis +/- urine culture
  • CXR regardless of symptoms
  • Nasopharyngeal swab for respiratory viruses
  • Stool for C.diff, if appropriate
  • If ongoing fevers, consider CT chest

Management

  • In general, broad-spectrum antimicrobials until fever resolved x48h AND neutrophils > 0.5 AND minimum course of 5-7 days, then consider stepping down to treat underlying infection only
  • Empiric antibiotic choice depends on site but should include pseudomonal coverage
  • Consider adding other agents empirically if concern for:
    • MRSA or SSTI or severe mucositis or septic shock: vancomycin 15mg/kg q12h, reassessed at 48h
    • Typhlitis: ensure adequate anaerobic coverage, may need to add metronidazole 500mg q12h
    • VRE: linezolid or daptomycin
    • ESBL: carbapenem
    • KPC: polymixin-colistin or tigecycline
  • If still febrile and neutropenic for 4 to 7 days despite antibiotics, add antifungal (especially if not on prophylaxis)
  • In high-risk patients, can consider adding GCSF (Neupogen/Filgrastim)
  • In some low-risk patients, can step down to amoxicillin-clavulanic acid AND ciprofloxacin 750
    • Expected duration of severe neutropenia ≀7 days, AND
    • No comorbidities or significant hepatic or renal dysfunction
    • Mostly, these patients are receiving chemotherapy for solid tumours
  • Monitor for myeloid reconstitution syndrome (similar to IRIS) while neutrophils are recovering

Resources

Further Reading